Introduction: Lung cancer risk prediction models have the potential to make programs more affordable; however, the economic evidence is limited.
Methods: Participants in the National Lung Cancer Screening Trial (NLST) were retrospectively identified with the risk prediction tool developed from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. The high-risk subgroup was assessed for lung cancer incidence and demographic characteristics compared with those in the low-risk subgroup and the Pan-Canadian Early Detection of Lung Cancer Study (PanCan), which is an observational study that was high-risk-selected in Canada. A comparison of high-risk screening versus standard care was made with a decision-analytic model using data from the NLST with Canadian cost data from screening and treatment in the PanCan study. Probabilistic and deterministic sensitivity analyses were undertaken to assess uncertainty and identify drivers of program efficiency.
Results: Use of the risk prediction tool developed from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial with a threshold set at 2% over 6 years would have reduced the number of individuals who needed to be screened in the NLST by 81%. High-risk screening participants in the NLST had more adverse demographic characteristics than their counterparts in the PanCan study. High-risk screening would cost $20,724 (in 2015 Canadian dollars) per quality-adjusted life-year gained and would be considered cost-effective at a willingness-to-pay threshold of $100,000 in Canadian dollars per quality-adjusted lifeyear gained with a probability of 0.62. Cost-effectiveness was driven primarily by non-lung cancer outcomes. Higher noncurative drug costs or current costs for immunotherapy and targeted therapies in the United States would render lung cancer screening a cost-saving intervention.
Conclusions: Non-lung cancer outcomes drive screening efficiency in diverse, tobacco-exposed populations. Use of risk selection can reduce the budget impact, and screening
Introduction
Early detection of lung cancer with low-dose computed tomography (LDCT) has been established as the most powerful approach available improve the cure rate of the world's most common cause of cancer deaths. 1, 2 In 2011 evidence from the National Lung Cancer Screening Trial (NLST) showed that lung cancer mortality rates can be reduced by as much as 20% with the use of LDCT as a screening intervention. 3 Subsequently, the U.S. Preventive Services Task Force recommended screening individuals between 55 and 80 years of age who have smoked at least 30 pack-years (e.g., one pack of cigarettes per day for 30 years) and have had fewer than 15 years of smoking abstinence immediately before screening. 4 The Centers for Medicare and Medicaid Services endorse lung cancer screening, and several other organizations now recommend a set number of, or an ongoing schedule of, annual and/or biennial LDCT screenings using selection criteria based primarily on age and smoking history. 5, 6 Using age and smoking history as risk factors for screening selection would qualify an estimated 8.6 million Americans as eligible for lung cancer screening. 7 The sheer volume of LDCT scans required to screen the general population, with age and smoking history as the sole selection criteria, would have major budgetary impacts and could unnecessarily expose low-risk individuals to potential screening harm. 8, 9 In addition, the U.S. Preventive Services Task Force selection criteria, which compromise NLST-like selection criteria, correlate poorly with the characteristics of patients with lung cancer, providing further reason to look beyond age, smoking history, and years of abstinence as predictive factors for selecting individuals for lung cancer screening. 10 Post-NLST research interests have thus focused on the use of risk prediction to select individuals according to additional risk factors with the aim of reducing the number needed to screen. 11, 12 There are several risk prediction models under investigation to improve the selectivity of lung cancer screening criteria. A recent comparative study showed that the risk models developed from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial have the best sensitivity and specificity to assess lung cancer risk. [13] [14] [15] Policy decisions to implement such programs are, however, limited by the availability of population-level evidence to forecast health system impacts. 16, 17 In the absence of such evidence, simulation models have been instrumental. These models suggest that early detection rates (i.e., ability to detect and curatively treat early stage disease before it develops into late-stage lung cancer), 18, 19 lung cancer-specific mortality reduction, 20 program costs, [20] [21] [22] smoking cessation rates, 21, [23] [24] [25] screening interval, 24 and screening bias (such as leadtime bias and overdiagnosis) are important aspects of lung cancer screening. 19, 25 A recent economic analysis of the NLST suggests that because screening reduces lung cancer deaths, it could also be cost-effective; however, the estimates of incremental cost-effectiveness ratios (ICERs) had too much uncertainty associated with them to offer statistically robust conclusions. 16, 26 Additional studies are needed not only to adequately inform policy with evidence but also to identify areas of future research that could improve the early detection and treatment of lung cancer. In this study, we used a PLCO Cancer Screening Trial-based risk prediction model to retrospectively calculate risk in the NLST. We compared the demographic characteristics of the high-risk subgroup of the NLST with those of the individuals in the Pan-Canadian Early Detection of Lung Cancer (PanCan) study, which selected screening participants according to individual risk scores. We then used a decision-analytic model to identify program areas that are likely to make lung cancer screening programs more efficient.
Methods

NLST Risk Assessment
Data from the NLST (NCT00047385) were provided by the National Institutes of Health according to a data transfer agreement. The protocol and initial results from the NLST are available in the literature. 27, 28 We used demographic data from the NLST and calculated risk with the PLCO m2009 risk prediction; the PLCO m2009 risk prediction model is an earlier version of the PLCO m2012 model that was developed from the PLCO trial. 15, 29 The PLCO series of models share similar predictors (i.e., age, education, smoking history, coexisting chronic obstructive pulmonary disease, family history of lung cancer, and body mass index), however, the PLCO m2012 also accounts for personal history of cancer and race/ethnicity. The PLCO m2012 has improved predictive value; however, the PLCO m2009 was chosen in this study to match the model used to select high-risk participants for the PanCan study (NCT00751660). The NLST participants were separated into high-risk (! 2% at 6 years) and low-risk (< 2% at 6 years) subgroups according to their PLCO m2009 score (Fig. 1) . A 2% cutoff threshold was selected in the PanCan study to ensure that the study recruitment goals were met. The outcomes data for NLST participants were grouped according to risk (high or low) and screening intervention (LDCT or chest radiography [CXR] ). We used a z test for proportions to assess heterogeneity between the high-risk NLST (HR-NLST) and low-risk NLST subgroups and between the HR-NLST and the PanCan study cohort (Table 1) . A two-sided p value less than 0.05 was considered statistically significant.
Decision Analysis
A decision-analytic model was developed to compare high-risk lung cancer screening to standard care (Fig. 2) . The base case scenario drew a comparison of LDCTbased screening in the HR-NLST (intervention) with the high-risk CXR (HR-CXR) screened arm (comparator) of the NLST, using the assumption that CXR is similar to standard care for early lung cancer detection. 30 The NLST outcomes data were sorted according to study arm and risk group.
In the intervention arm, three Markov models were used to project long-term outcomes for different risk groups and possible screening participation rates from the data for participants in the NLST. The Markov models were as follows: the high-risk screening model, which was used to simulate high-risk participants who were screened for lung cancer with LDCT; the high-risk unscreened model, which simulated outcomes from unscreened, high-risk individuals using data for the HR-CXR subgroup of the NLST; and the low-risk unscreened model, which simulated outcomes for unscreened, low-risk participants from the CXR arm of the NLST. The comparator arm simulated costs and outcomes with the high-risk unscreened model and low-risk unscreened model only.
All simulated subjects entered the Markov model at the start of year 1, in the screening health state (Fig. 2B) .
Transitions from the screening state were calculated from the initial date of the baseline screening examination to the first day of curative treatment, noncurative treatment, withdrawal, or death, whichever occurred first. Transitions to curative treatment were assigned for participants with pathologic stage IA to IIB lung cancer and stage IIIA lung cancer that included surgery as part of first-line treatment. Noncurative treatment was defined as any treatment for stage IIIB to stage IV lung cancer and any treatment for stage IIIA lung cancer that did not include surgery. Progression after curative treatment was determined from the NLST progression data for all participants who had initially received a firstline curative treatment. Transitions from the curative or noncurative health states (i.e., those occurring after firstline treatment) were calculated from the date of lung cancer treatment to the earliest date of progression or death. Annual transition probabilities were calculated according to the shape and slope parameters of Weibull curves estimated by using time to event data from the NLST. The rate of background all-cause mortality was incorporated for all posttrial outcomes by using Canadian life tables from Statistics Canada 31 and assuming an average age of screening enrollment of 60 years.
Costs and outcomes for individual health states in the Markov models were calculated annually on the basis of probability of transitioning between the five possible Markov health states ( Fig. 2B ) with a 1-year cycle length. Health utility (preference-based quality of life) inputs from the PanCan study and literature 32, 33 were applied to each health state in the model to enable calculation of quality-adjusted life-years (QALYs) from the NLST outcomes (see Supplementary Material). Tunnel health state transitions were programmed after lung cancer treatment to incorporate time-varying parameters into the Markov models. The additional cost of the intervention arm, in 2015 Canadian dollars, was divided by the cumulative gain in QALYs. Future costs and QALYs were discounted to their present value at a rate of 3% per year, and the simulation was run over a lifetime horizon (30 years) . A deterministic sensitivity analysis was undertaken to test for isolated parameter uncertainty, and a probabilistic sensitivity analysis (PSA) was undertaken to test for combined parameter uncertainty throughout the model. 
Cost Analysis
Costs from the public payer's perspective were determined from resource utilization data in the PanCan study. We used Canadian cost data to project cost impacts in a universal access health care system. The methods of cost analysis are described in further detail in the Supplementary Material and in a previous publication from our group. 30 Briefly, resource utilization data for all direct medical costs (diagnostic imaging, cardiopulmonary testing, endoscopy, biopsy, surgery, chemotherapy, radiotherapy, adverse events, and inpatient resources related to the early detection and treatment of lung cancer) were prospectively collected for PanCan study participants screened with LDCT, and grouped annually starting from the point of a health state transition multiplied by Canadian unit costs and expressed as an average per-person cost, in 2015 Canadian dollars (1 Canadian dollar z $0.75 U.S.) for each of the health states in the model. Annual screening costs were applied over the first 15 years under the assumption that screening examinations and investigations are ongoing. Screening costs in the comparator arm were conservatively assumed to equal zero. Societal (patient-borne) costs and the costs of incidental findings during screening were calculated from data collected in the PanCan study and assessed in the deterministic analysis (see the Supplementary Material).
Uncertainty and Impact of Screening Parameters
Uncertainty throughout the model was assessed by using a PSA. The PSA used Monte Carlo simulation, which involved random sampling from distributions assigned to each of the input parameters. Cost data were sampled from gamma distributions weighted to sample means and the SEs of the data. Transition probabilities in the PSA were expressed as beta distributions for dichotomous health transitions (e.g., transitions that occur from noncurative treatment to either continued survival or death) and Dirichlet distributions for health states with more than two options for transition (e.g., transitions from the screening health state to curative treatment, noncurative treatment, or death).
To investigate drivers of program efficiency we made isolated changes to individual model parameters by using the SE limits of the input data in a deterministic analysis ( Table 2) . We assessed the impact of selection criteria by using the general NLST data without risk stratification. We also tested specific scenarios that have been discussed in the literature, including societal costs, the costs of investigating incidental findings, the impact of overdiagnosis, greater stage shift (higher ratio of curative to noncurative treatment of early-detected lung cancer), higher transitions to noncurative treatment in postscreening years, and higher future drug costs.
Results
Risk Selection
The data set for the NLST is maintained by the National Cancer Institute, and a version of the study results was provided for this study in 2015. The data we received covered a total of 53,452 randomized participants. Previous publications of the study reported for 53,454 NLST participants before the withdrawal of two participants from the study. The data that we used also differed from the data of previous reports by an additional 204 ineligible participants identified in the data we used. The most common reasons for ineligibility included receipt of another computed tomography examination less than 18 months before enrollment (n ¼ 71), enrollment in another screening trial (n ¼ 28), and having a diagnosis of cancer within the past 5 years (n ¼ 24); the remaining ineligible participants did not meet the age, smoking history, or health requirements to participate in the NLST. We excluded a further 3473 participants without the required information to calculate individual risk and transition probabilities for this study (see Fig. 1 ).
There were 49,775 eligible participants (93.1% of the original number) with all of the required information available for our study. Of these, 9788 (19.7%) had a calculated risk for development of lung cancer over 6 years of 2% or higher. Of the total 1891 lung cancer cases reported in the NLST data with all of the risk assessment criteria, 163 were excluded from the analysis on account of absence of staging and/or treatment information required to assign health state transitions.
The HR-LDCT subgroup included more curative lung cancer cases than the HR-CXR subgroup (4.7% versus 3.2% [p < 0.05]) and fewer detected lung cancer cases in which noncurative treatment was received (2.8% versus 3.7% [p < 0.05]). Those in the low-risk LDCT (LR-LDCT) subgroup also had more curative treatments than those in the low-risk CXR subgroup: 1.6% versus 1.0% curative (p < 0.05) over the median 6.4 years of follow-up for the NLST.
High-Risk Populations
There were major differences between the characteristics of the HR-NLST participants and those of participants enrolled in the PanCan study (see Table 1 ). When compared with participants in the PanCan study, the members of HR-NLST subgroup were more likely to be male, were less likely to be white, were more likely to be older than 65 years, had fewer years of formal education, had more comorbidities, had more pack-years and years of smoking history, and had a lower body mass index (p < 0.05 for each categorical demographic characteristic). Significant categorical differences were also observed when the HR-NLST subgroup was compared with the low-risk NLST subgroup. There were 793 lung cancer cases detected in the high-risk NLST (416 in the HR-LDCT subgroup and 377 in the HR-CXR subgroup) (an 8.1% detection rate) and 1098 in the lower-risk subgroup (582 in the LR-LDCT subgroup and 516 in the low-risk CXR subgroup) (a 2.7% detection rate), with a significantly higher lung cancer incidence in the highrisk subgroup (p < 0.05).
Cost Impact
The average per-person cost to screen individuals in the intervention arm was low, totaling less than $500 per year (Table 3 31-33 ). The costs associated with treating progression (curative failures) and noncurative treatment reached $28,888 per year on average; noncurative costs were driven mostly by resource use for inpatient palliative care and costs related to chemotherapy (see the Supplementary Material). All drugs assessed in the cost analysis were either cytotoxic or targeted drugs provided under compassionate access agreements in Canada (zero cost) at the time of the study. The drugs assessed have lower prices than the targeted drugs that are currently under consideration for reimbursement in Canada.
The average societal cost for screening participants added $209 to first-year screening costs and that amount decreased by 50% in all subsequent years. The annual societal costs to treat lung cancer noncuratively added a maximum of $17,447 per person, per year on average; $12,235 of which was attributed to lost productivity for patients who had previously been working before their lung cancer treatment-the remaining $5111 was for out-of-pocket expenses related to attending treatment-related appointments annually. Patients with lung cancer are assumed to have 100% health insurance and chemotherapy drug coverage, as is the case in British Columbia, where the societal cost data were collected. Patients who had curative treatment for lung cancer had an additional $6083 for societal costs in the first year of treatment but less than $230 per year in all subsequent years (see Supplementary Material).
Cost-Effectiveness
In the base case scenario (high-risk LDCT screening versus standard care), the intervention offered a gain of 0.032 QALYs, at an average increased cost of $668 per person (see Table 3 ). The ICER was $20,724 per QALY. The probabilistic sensitivity analysis indicated that the intervention would be considered cost-effective in 62% of the iterations in jurisdictions that are willing to pay $100,000/QALY. There was a small sample size to inform observed transitions from curative treatment to progression and curative treatment to death in the HR-NLST. Potential impacts from the uncertainty around these parameters were investigated deterministically and found to have no impact on the cost-effectiveness results. The deterministic analysis (see Table 2 ) revealed that screening mortality rates had the greatest impact on cost-effectiveness. Quality of life for screening participants (but not for patients receiving lung cancer treatment) also had an appreciable impact on the cost-effectiveness of lung cancer screening. Taking the societal cost perspective and including the cost of incidental findings from screening examinations raised the ICER only moderately. A tenfold increase in noncurative treatment costs would make lung cancer screening a cost-saving intervention. All other parameters tested did not have an appreciable impact.
Discussion
Our findings concur with the suspected economic benefits of risk selection and fulfill an unmet need for conclusive economic evidence for lung cancer screening. The economic benefits of risk selection come from the ability to reduce the overall budget impact of screening by excluding low-risk participants; however, risk selection did not improve on the cost-effectiveness of the LDCT intervention. Cost-effectiveness was driven primarily by non-lung cancer outcomes, such as mortality reductions or long-term improvements to quality of life for participants without lung cancer; thus, The two-way deterministic analyses varied inputs plus or minus the SE of the sample means used in the base case scenario; unidirectional (one-way) analyses tested a targeted increase to one parameter in the targeted scenarios. QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio; HRSM, high-risk screening model; HR, high risk; PanCan, Pan-Canadian Early Detection of Lung Cancer Study; NLST, National Lung Cancer Screening Trial; LDCT, low-dose computed tomography; CXR, chest radiography. n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a Noncurative lung cancer treatment n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a a Costs for screening were assumed to be zero and quality of life was the same as year 1 screening in the comparator arm. b Quality of life during screening was estimated from the EQ-5D-3L questionnaires completed by PanCan study participants. e Quality of life during for lung cancer progression was referenced from EQ-5D-3L results for relapsed lung cancer, reported by Jang et al. 33 HR-LDCT, high-risk portion of the NLST screened with low-dose computed tomography; HR-CXR, high-risk portion of the NSLT screened with chest radiography; n/a, not available; EQ-5D-3L, European Qualify of Life Five-Dimension Three-Level questionnaire; PanCan, Pan-Canadian Early Detection of Lung Cancer Study.
improvements to cost-effectiveness are most likely to come from improvements to non-lung cancer outcomes. Quality of life improvements, as measured by the European Qualify of Life Five-Dimension Three-Level questionnaire, include generic health status, measures of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Low-cost interventions known to improve quality of life, such as smoking cessation, are therefore likely to make screening programs more costeffective. If early lung cancer detection and treatment improve with better clinical management (i.e., more precise screening selection, fewer false-positive examination results, and more successful early-stage treatments), the cost-effectiveness of screening will also improve, making lung cancer screening one of the most cost-effective cancer interventions available. Adaptations to screening programs to achieve this goal have had promising results. Some examples include the use of smoking cessation interventions alongside screening, modification of heart disease risk by using statins in those with severe coronary artery calcification, and improved lung nodule management to reduce false-positive results. [34] [35] [36] [37] [38] The impacts of non-lung cancer outcomes were not accounted for in the cost-effectiveness analysis of the NLST published in 2011 by Black et al., which relied on U.S. registry data for lung cancer mortality rates to project lifetime benefits. 16 We found that it was necessary to include outcomes from most individuals that are affected by the intervention in long-term modeling. This difference is an important development because high-risk screening participants, in whom lung cancer is more likely to develop, also have greater comorbidities related to their tobacco exposure. The costs of screening in the United States are comparable to the costs in Canada; however, noncurative drugs in the United States tend to cost two to 10 times more than the drugs used in Canada. 39, 40 Higher drug costs in the United States and higher costs of new targeted therapy and immunotherapy agents would make screening more cost-effective. Our results are therefore conservative in estimating the economic impact of lung cancer screening in the United States.
Our study is limited by the inability to extend results from a single randomized trial with three annual screens and a median follow-up of 6.4 years to the general population, which may have a different screening protocol, such as annual screening until the age of 77. The high degree of heterogeneity between the high-risk participants in the NLST and in PanCan studies indicates that screening may also enable access to care in nonuniversal health care systems. Indeed, a statistically significant reduction in all-cause mortality for black NLST participants screened by LDCT has suggested that the intervention may also enable treatment for tobacco-related illness in this subgroup of the NLST. 41 The PLCO m2012 and PLCO m2009 models partly address issues of equitable access to screening by including socioeconomic status (formal education level) in the risk assessment, thus enriching those in lower socioeconomic groups.
The PLCO m2009 model used in this study and the 2% over 6 years threshold used for this analysis missed 582 lung cancer cases in the LR-LDCT screening arm. Future studies in a heterogeneous population, such as those at risk for lung cancer, will need to understand and balance the benefit of minimizing the number of individuals required to be screened with the cost of missing lung cancer cases if less accurate models or thresholds higher than the 2% cutoff point are used. Refinements to the PLCO m2009 model have led to the improved PLCO m2012 model, which is now ranked as one of the most specific and selective models available. 15 The use of more refined risk prediction models with better predictive power will be required to reduce false-negative selection results and preventable lung cancer deaths.
In conclusion, high-risk lung cancer screening with LDCT is likely to be considered cost-effective and the use of refined risk prediction tools before LDCT-based screening selection can reduce the budget impact. Improvements to the quality and quantity of life for screened individuals can improve the overall costeffectiveness of LDCT-based lung screening, and effective interventions such as smoking cessation and reduction of coronary risk should be investigated for their potential to further improve program efficiency.
